title: Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline.
abstract: Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.
authors.affiliation: Institutes of Hygiene and Social Medicine, University of Innsbruck, Austria. Cornelia.Lass-Floerl@uibk.ac.at
authors.forename: C
authors.initials: C
authors.lastname: Lass-Flörl
authors.forename: M P
authors.initials: MP
authors.lastname: Dierich
authors.forename: D
authors.initials: D
authors.lastname: Fuchs
authors.forename: E
authors.initials: E
authors.lastname: Semenitz
authors.forename: M
authors.initials: M
authors.lastname: Ledochowski
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011293:Premenstrual Syndrome / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020280:Sertraline / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline